InterVenn Biosciences to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum

InterVenn Biosciences announced Company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 17, 2022 at 2:30 p.m. Eastern Time.

Codetta Biosciences and North Carolina Central University Receive $2M Grant from the North Carolina Collaboratory

New funding will allow Codetta and NCCU to advance COVID related research and future clinical care

The U.S. Department of Defense Taps Xendee to Optimize Microgrid Design for Military Installations

Xendee’s integrated platform provides a standardized approach that cuts microgrid design time, slashes engineering expenses, and is scalable across the Department of Defense.

MedCrypt Raises $25M Series B for Continued Growth and Innovation in Medical Device Cybersecurity

MedCrypt will use the funds for the continued delivery of proactive cybersecurity solutions to help medical device manufacturers meet cybersecurity requirements set by the FDA and international regulators

Anzu Partners Named to Inc.’s 2022 List of Founder-Friendly Investors

For the second consecutive year, Inc. recognized Anzu Partners for its commitment to breakthrough technology founders and entrepreneurs

OTI Lumionics Raises $55 Million in Series B Funding and Completes Customer Mass Production Qualification of its Display Materials

The company’s technology enables the front facing camera and other sensors to be integrated under the display, eliminating notches and cut-outs in mobile devices screens

Erwin Estigarribia is Appointed President and Chief Operating Officer of InterVenn Biosciences

InterVenn is focusing on the development and commercialization of its Advanced Adenoma and Colorectal Cancer screening platform to change the paradigm for the detection of early-stage disease

AM Batteries (AMB) Secures $25M Series A Financing to Scale Manufacturing of Novel Lithium-Ion Dry-Electrode Technology

AM Batteries (AMB) is a Boston-based innovative manufacturing company developing a next-generation, lower-carbon footprint and lower cost dry-electrode manufacturing technology for lithium-ion batteries

Xendee Microgrid Design Platform Adds New Feature to Help Engineers Take Advantage of Inflation Reduction Act Incentives

Xendee platform now offers tools to apply these incentives directly to the technologies during the modeling process.

Excision BioTherapeutics to Host Key Opinion Leader Webinar on HIV and the Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure

Webinar will focus on the unmet medical need in HIV, therapeutic applications of gene delivery and editing for treatment of viral disease, and the Company’s ongoing Phase 1/2 trial evaluating the CRISPR-based therapy, EBT-101, as a treatment for HIV